Lawrence Nathan Shulman, MD

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Abramson Cancer Center
3400 Civic Center Boulevard
Perelman Center for Advanced Medicine
South Pavilion, 12-111
Philadelphia, PA 19104
Education:
B.A. (Organic Chemistry)
Syracuse University, 1971.
M.D. (Medicine)
Harvard Medical School, 1975.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Lawrence N. Shulman, MD, is the Deputy Director for Clinical Services of the Abramson Cancer Center at the University of Pennsylvania, and Director of the Center for Global Cancer Medicine. In this capacity, he leads the Cancer Quality program and strategic development of Cancer Services. He received his MD from Harvard Medical School, and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.

Dr. Shulman is currently Chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academy. He is the former Chair of the American Society of Clinical Oncology Quality of Care Committee and the Commission on Cancer’s Quality Integration Committee.

A specialist in the treatment of patients with breast cancer, his research includes development of new cancer therapies, and implementation of cancer treatment programs in low-resource settings.

In this regard, Dr. Shulman serves as Senior Oncology Advisor to the non-profit organization Partners In Health (PIH). The PIH mission includes the establishment of national cancer treatment programs with the Ministries of Health in Rwanda and Haiti, programs for which he plays a seminal leadership role. He sits on the Vice Chancellor’s Advisory Council for Rwanda’s University for Global Health Equity. In addition, he helps to lead the development of the national oncology program in Botswana through the Botswana-UPenn Partnership. Dr. Shulman is a former member of ASCO’s International Affairs Committee and their Task Force on Global Oncology as an Academic Career. He led the World Health Organization’s review and revision of their Essential Medicines for Cancer from 2014-2017.

He received his MD from Harvard Medical School, and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.

Selected Publications

Butonzi J, Forbes V, Kigonya C, Lansigan F, Davis T, Figueroa K, Ruhangaza D, Shabani K, Nininahazwe P, Nkunsi E, Habimana O, Haley J, Buswell L, Costa C, Hill A, Sharma P, Hanna C, Fehr A, DeBoer B, Park P, Sebahungu F, Mpanumusingo E, Shyirambere C, Mpunga T, Shulman LN, Chamberlin M: Global oncology fellowship electives: The impact on cancer care and international collaborations. Rwanda Med J 2019, in press.

Vapiwala N, Thomas CR, Grover S, Yap ML, Mitin T, Shulman LN, Gospodarowicz MK, Longo J, Petereit DG, Ennis RD, Hayman JA, Rodin D, Buchsbaum JC, Vikram B, Abdel-Wahab M, Epstein AH, Okunieff P, Goldwein J, Kupelian P, Weidhaas JB, Tucker MA, Boice JD, Fuller CD, Thompson RF, Trister AD, Formenti SC, Barcellos-Hoff MH, Jones J, Dharmarajan KV, Zietman AL, Coleman CN: Enhancing career paths for tomorrow’s radiation oncologists. Int J Radiat Oncol Biol Phys Sept 2019.

Kline RM, Rocque GB, Rohan EA, Blackley KA, Cantril CA, Pratt-Chapman ML, Burris HA, Shulman LN: Patient navigation in cancer: The business case to support clinical needs. J Oncol Prac Sept 2019.

Schleimer LE, Dusengimana JMV, Butonzi J, Kigonya C, Natarajan A, Umwizerwa A, O’Neil DS, Costas-Chavarri A, Majyambere JP, Shulman LN, Keating NL, Shyirambere C, Mpunga T, Pace LE: Barriers to timely surgery for breast cancer in Rwanda. J Surg Aug 2019.

Pomponio MK, Keele LJ, Fox KR, Clark AS, Matro JM, Shulman LN, Tchou JC: Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer? Breast Cancer Res Treat Aug 2019.

Shulman LN, Browner AE, Palis BE, Mallin K, Kakade S, Carp N, McCabe R, Winchester D, Wong SL, McKellar DP: Compliance with cancer quality measures over time and their association with survival outcomes: The Commission on Cancer’s experience with the quality measure requiring at least 12 regional lymph nodes are removed with colon cancer resections. Ann Surg Oncol June 2019.

Dao D, Zemla T, Jatoi A, Freedman RA, Hurria A, Muss H, Cohen HJ, Shulman LN, Citron M, Budman D, McMurray R, Partridge A, Carey L, Sedrak MS, Lafky JM, Le-Rademacher JG : Older-patient-specific cancer trials: A pooled analysis of 2,277 patients (A151715). Oncologist 24: e284-e291, June 2019.

Lopez D, Pratt-Chapman ML, Rohan EA, Sheldon LK, Basen-Engquist K, Kline R, Shulman LN, Flores EJ: Establishing effective patient navigation programs in oncology. Support Care Cancer 27(6): 1985-1996, June 2019.

Mehta S, Weber K, Fleisher L, Shulman LN, Gabriel P, Trerotola SO, Nawas M, Chi AS, Sebro R: Assessing the need for preprocedural laboratory tests and stopping non-steroidal anti-inflammatory drugs/aspirin in patients undergoing percutaneous bone and soft tissue biopsies. Cardiovasc Intervent Radiol June 2019.

Nekhlyudov L, Mollica MA, Jacobsen P, Mayer DK, Shulman LN, Geiger AM: Developing a quality of cancer survivorship care framework: Implications for clinical care, research, and policy. J Natl Cancer Inst May 2019.

back to top
Last updated: 11/19/2019
The Trustees of the University of Pennsylvania